Skip to content

Menu

About CLTI
Technology
- Products
Clinical Evidence
U.S. Clinical Trial
Company
- Management
- Clinical Advisors
- News
- Media
- Articles
Contact
International

June 6 2017

LimFlow Expands Senior Management Team and Opens Silicon Valley Office

View the article.

LimFlow Receives FDA Approval for U.S. Feasibility Study of Minimally-Invasive Technology Designed to Restore Perfusion in “No Option” Critical Limb Ischemia Patients Midterm Outcomes From a Pilot Study of Percutaneous Deep Vein Arterialization for the Treatment of No-Option Critical Limb Ischemia

Related Posts

LIMFLOW APPOINTS JENNY GAFFNEY AS VICE PRESIDENT, HEALTH ECONOMICS AND REIMBURSEMENT

LIMFLOW RAISES $40 MILLION (€36 MILLION) IN SERIES D FINANCING

US PIVOTAL STUDY AND CLARITI COMPLETE ENROLLMENT

Recent Posts

LIMFLOW APPOINTS JENNY GAFFNEY AS VICE PRESIDENT, HEALTH ECONOMICS AND REIMBURSEMENT
LIMFLOW RAISES $40 MILLION (€36 MILLION) IN SERIES D FINANCING
US PIVOTAL STUDY AND CLARITI COMPLETE ENROLLMENT
LATE-BREAKING DATA FROM PROMISE I STUDY ON LIMFLOW SYSTEM CONFIRM EXCELLENT SUSTAINED OUTCOMES IN PATIENTS WITH NO-OPTION CHRONIC LIMB-THREATENING ISCHEMIA
THE LIMFLOW SYSTEM FOUND TO BE COST-EFFECTIVE, ACCORDING TO THE NEWEST STUDY PUBLISHED IN THE JOURNAL OF CRITICAL LIMB ISCHEMIA

LimFlow, Inc.
3031 Tisch Way
110 Plaza West
San Jose, CA 95128
United States of America

info@limflow.com
+1 (888) 478-7705
+1 (408) 898-1459

CAUTION: Investigational device. Limited by Federal law to investigational use. | Privacy Policy

©2022 LimFlow SA | Site designed by The Deciding Factor, Inc.